Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login

Research Library

A-Z Conditions  Participate in ORR

A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome

  • Journal : Cannabis and Cannabinoid Research
  • Publication Year : 2023
  • Authors : Elia Abi-Jaoude, tracy Bhikram, Ferdous Parveen, Jody Levenbach, Myriam Lafreniere-Roula, & Paul Sandor

Please use this link to access this publication: https://www.liebertpub.com/doi/full/10.1089/can.2022.0091

Abstract

Background: The number of effective evidence-based treatment options for patients with Tourette syndrome (TS) is limited. Emerging evidence shows cannabinoids as promising for the treatment of tics.

Objectives: To compare the efficacy and tolerability of single doses of three vaporized medical cannabis products and placebo in reducing tics in adults with TS.

Methods: In a randomized, double-blind, crossover design, each participant received a vaporized single 0.25 g dose of Δ9-tetrahydrocannabinol (THC) 10%, THC/cannabidiol (CBD) 9%/9%, CBD 13%, and placebo at 2-week intervals. Our primary outcome was the Modified Rush Video-Based Tic Rating Scale (MRVTRS), taken at baseline and at 0.5, 1, 2, 3, and 5 h after dose administration. Secondary measures included the Premonitory Urge for Tics Scale (PUTS), Subjective Units of Distress Scale (SUDS), and Clinical Global Impression–Improvement (CGI-I). Correlations between outcomes and cannabinoid plasma levels were calculated. Tolerability measures included open-ended and specific questions about adverse events (AEs).

Results: Twelve adult patients with TS were randomized, with nine completing the study. There was no statistically significant effect of product on the MRVTRS. However, there was a significant effect of THC 10%, and to a lesser extent THC/CBD 9%9%, versus placebo on the PUTS, SUDS, and CGI-I. As well, there were significant correlations between plasma levels of THC and its metabolites, but not CBD, with MRVTRS, PUTS, and SUDS measures. There were more AEs from all cannabis products relative to placebo, and more AEs from THC 10% versus other cannabis products, particularly cognitive and psychomotor effects. Most participants correctly identified whether they had received cannabis or placebo.

Conclusions: In this pilot randomized controlled trial of cannabis for tics in TS, there was no statistically significant difference on the MRVTRS for any of the cannabis products, although the THC 10% product was significantly better than placebo on the secondary outcome measures. Also, THC and metabolite plasma levels correlated with improvement on all measures. The THC 10% product resulted in the most AEs. ClinicalTrials.gov ID: NCT03247244.

Read the Full Article

Share This:

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
PrevPreviousThe Effect of Cannabis Plant Extracts on Head and Neck Squamous Cell Carcinoma and the Quest for Cannabis-Based Personalized Therapy
NextDifferences in cannabis use characteristics, routines, and reasons for use among individuals with and without a medical cannabis cardNext

Conditions:

  • Tourette's syndrome

Research Information:

Research Keywords:

  • ∆9-tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabis

Search the Research Library >

Follow Us:

Facebook Twitter Youtube

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2024 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer

Open the following in new tabs if you:

If you are already a user: Client Login

If you are not, then register: Client Registration

Once Logged in, click below to refresh the page.